Acorda is down 6%, Auxilium is down 35%, Dendreon is down 27%, and Momenta is down 30%.

FORBES: Biotech, Where Winners Lose

This piece was written by Ron Cohen, the chief executive of Acorda Therapeutics.

FORBES: How The U.S. Can Attract Biotech Firms By Imitating China

Ampyra, a pill approved to help patients with multiple sclerosis walk, has put Acorda Therapeutics in the small club of profitable biotechnology companies.

FORBES: Drug That Helps Multiple Sclerosis Patients Walk May Also Aid Stroke Victims

Acorda's drug, Fampridine-SR, works differently from dirucotide and specifically addresses one of the most devastating symptoms of the disease, loss of muscle strength.

FORBES: Two Steps Forward

The results will need to confirmed in a much bigger clinical trial, the design of which Acorda will need to discuss with the Food and Drug Administration.

FORBES: Drug That Helps Multiple Sclerosis Patients Walk May Also Aid Stroke Victims

Acorda is also examining Ampyra for use in cerebral palsy.

FORBES: Drug That Helps Multiple Sclerosis Patients Walk May Also Aid Stroke Victims

Cohen founded Acorda Therapeutics, Inc. in 1995.

FORBES: How The U.S. Can Attract Biotech Firms By Imitating China